BIOHARVEST SCIENCES INC. BHST
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $34.5M | $25.2M | $12.7M | — |
| Cost of revenue | $14.0M | $11.2M | $7.0M | — |
| Gross profit | $20.5M | $13.9M | $5.6M | — |
| Total operating expenses | $26.1M | $20.9M | $15.6M | — |
| Operating income | -$5.6M | -$7.0M | -$10.0M | — |
| Pre-tax income | -$11.1M | -$12.9M | -$12.6M | — |
| Income tax | $76.0K | $8.0K | $0 | — |
| Net income | -$11.1M | -$12.9M | -$12.6M | — |
| EPS, basic | -0.60 | -0.80 | -0.93 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $23.0M | $2.4M | $5.4M | $1.7M |
| Receivables | $2.0M | $1.1M | $808.0K | — |
| Inventory | $4.6M | $3.7M | $2.5M | — |
| Total current assets | $30.5M | $7.9M | $9.1M | — |
| Property, plant and equipment | $8.3M | $7.8M | $3.9M | — |
| Total assets | $47.7M | $25.0M | $15.0M | — |
| Accounts payable | $2.6M | $3.5M | $1.8M | — |
| Short-term debt | $149.0K | $3.9M | $0 | — |
| Total current liabilities | $7.7M | $14.3M | $26.5M | — |
| Retained earnings | -$107.6M | -$96.4M | -$83.5M | — |
| Total equity | $25.4M | $1.3M | -$14.9M | -$5.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$6.7M | -$8.5M | — |
| Depreciation and amortisation | $1.6M | $1.3M | $840.0K | — |
| Capital expenditure | $2.4M | $2.8M | $1.5M | — |
| Investing cash flow | -$2.4M | -$3.0M | -$1.5M | — |
| Financing cash flow | $30.2M | $6.8M | $13.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001376474-26-000257.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $12.7M | $25.2M | $34.5M |
| Gross profit | — | $5.6M | $13.9M | $20.5M |
| Net income | — | -$12.6M | -$12.9M | -$11.1M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |